Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial | GenomeWeb

Vertex Pharmaceuticals has announced positive interim results this month from the second part of an ongoing Phase II trial examining a combined regimen of its approved drug Kalydeco and its newer treatment VX-809 in cystic fibrosis patients with the F508del mutation. After 56 days of treatment, adult subjects homozygous for the mutation have shown significant improvement in lung function, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.